Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405] [Amend] SEC Accession No. 0000899866-17-000012 Filing Date 2017-01-19 2017-01-19 17:14:33 Period of Report 2015-12-31 Filing Date Changed 2017-01-19 Document ... SEC Filings, 23 hours ago
Jan.10.17 | About: Alexion Pharmaceuticals, (ALXN) The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this event. ClickSeeking Alpha, 1 week ago Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference Pharmacy Choice, 4 days ago Alexion Pharmaceuticals To Present At J.P.Morgan Conference; Webcast At 11:00 AM Nasdaq, 1 week ago ALEXION PHARMACEUTICALS : to Present at the 35th Annual J.P. Morgan Healthcare Conference 4 Traders, 2 weeks ago
ALEXION PHARMACEUTICALS : Submits U.S. and EU Applications Seeking Approval of Soliris® Eculizumab as a Treatment for Patients with Refractory Generalized Myasthenia...
Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® Eculizumab as a Treatment for Patients with Refractory Generalized Myasthenia Gravis gMG By a News Reporter-Staff News Editor at Biotech Week -- Alexion Pharmaceuticals, Inc.4 Traders, 1 day ago Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 Freshnews.com, 6 days ago Alexion submits marketing applications for expanded use of Soliris Seeking Alpha, 1 week ago Alexion Pharma Announces Regulatory Submissions To Extend Indication For Soliris Quotenet.com, 1 week ago
Jan 9 (Reuters) - Alexion Pharmaceuticals Inc * Alexion interim CEO says they are not up for sale - JPM Healthcare conf * Alexion execs says growth is primarily coming from volume, not pricing- JPM Healthcare conf * Alexion execs say they are ...Business Insider, 1 week ago
Image source: . What happened Shares of rare-disease specialist Alexion Pharmaceuticals, Inc. ( NASDAQ:ALXN ) slid 35.9% lower last year, according to data from S&P Global Market Intelligence . Disturbing clinical trial results for its lead ...Motley Fool, 1 week ago
• Alexion Pharmaceuticals, Inc's (ALXN) shares jumped 9.5% after forecasting earnings within the range of $4.50 to $4.65 per share for 2016, higher than the Zacks Consensus Estimate of $3.86 • Shares of CEB Inc. (CEB) climbed 20.9% following ...Yahoo! Finance, 2 weeks ago
More from: , Nasdaq...and 1 other sources
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN
NEW YORK, Jan. 12, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc. securities (NASDAQ: ALXN) from February 10, 2014 ...International Business Times, 1 week ago ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Alexion Pharmaceuticals, Inc. (ALXN) 4 Traders, 6 days ago Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN 4 Traders, 1 week ago Alexion faults tone at top, management pressure in Soliris investigation BioPharma Dive, 2 weeks ago
Shares of drugmaker Alexion Pharmaceuticals jumped more than 9 percent on Thursday after the company reiterated its 2016 forecast and said an internal investigation ended. In a Securities and Exchange Commission filing, Alexion said it continues to ...CNBC, 2 weeks ago Alexion shares zoom higher as sales probe ends with no need for restatement, backs 2016 forecast Yahoo! Finance UK and Ireland, 2 weeks ago
Drug company Alexion Pharmaceuticals (ALXN) has moved notably higher during trading on Thursday, advancing by 9.7 percent. Alexion reached a two-month intraday high earlier in the session. The advance by shares of Alexion comes after the company ...RTTNews.com, 2 weeks ago
Alexion Pharmaceuticals is speaking out about an internal investigation of its drug sales, and discloses a U.S. Attorney subpoena. That's on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host ...Bloomberg, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!